All News

24 March 2012

Daiichi Sankyo Files for Approval in Japan to Market AMG 162 (denosumab), a Treatment for OsteoporosisAntibodies

21 March 2012

Regeneron Announces Data Publication and Presentations with Potential First-in-Class Lipid-Lowering PCSK9 AntibodyAntibodies

19 March 2012

Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCLAntibodies

15 March 2012

Abbott Announces Patient Enrollment in Two Phase 3 Studies of HUMIRA® (adalimumab) for Moderate to Severe Hidradenitis SuppurativaAntibodies

13 March 2012

biOasis’ BT2111-Herceptin(R) Program Achieves Significant Positive Results From Antibody Dependent Cell-Mediated Cytotoxicity AssayAntibodies

9 March 2012

Peregrine Reports Data From Phase II Front-Line Lung Cancer TrialAntibodies

9 March 2012

Study Establishes XOMA’s XMetA as the First Allosteric Insulin Receptor-Activating Antibody to Improve Glycemic Control In VivoAntibodies

6 March 2012

MorphoSys Completes Enrollment in MOR103 Phase 1b/2a Rheumatoid Arthritis TrialAntibodies

5 March 2012

Anthera Pharmaceuticals Completes Interim Analysis of PEARL-SC Clinical Trial with BlisibimodAntibodies

3 March 2012

Recruitment of patients completed in phase II study with BI-204Antibodies

2 March 2012

Genentech’s ACTEMRA Monotherapy Showed Superior Improvement in Rheumatoid Arthritis Signs and Symptoms Versus Adalimumab MonotherapyAntibodies

27 February 2012

FDA approves protocol amendment needed to conduct the final analysis of the pivotal RENCAREX Phase III trialAntibodies

22 February 2012

UCB announces start of C-EARLY™ study for Cimzia (certolizumab pegol) in rheumatoid arthritisAntibodies

20 February 2012

Takeda Announces Primary Endpoints Met for Pivotal Phase 3 Trial of Vedolizumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Have Failed at Least One Conventional TherapyAntibodies

20 February 2012

Positive One Year results From Phase 3 Study in Central Retinal Vein Occlusion of VEGF Trap-EyeAntibodies

9 February 2012

In-vivo proof of concept achieved by targeting of IL1RAP on human tumorAntibodies

8 February 2012

Amgen to Discuss Application for New Use of XGEVA® (denosumab) at FDA Oncologic Drugs Advisory Committee MeetingAntibodies

8 February 2012

ARGEN-X ADVANCES A THIRD THERAPEUTIC ANTIBODY PROGRAM INTO PRECLINICAL DEVELOPMENTAntibodies

7 February 2012

FDA Grants Genentech’s Pertuzumab Priority Review for Previously Untreated HER2-Positive Metastatic Breast CancerAntibodies

2 February 2012

Compugen Cancer Target Results Demonstrate Significant Potential for Cancer ImmunotherapyAntibodies

30 January 2012

VGX-100 Identified as Potential New Therapy for Improving Corneal Graft SurvivalAntibodies

30 January 2012

biOasis Advances its Herceptin(R) BT2111 ProgramAntibodies

29 January 2012

Lpath Temporarily Suspends Dosing of iSONEP in Clinical Trials Due to cGMP Compliance Issues at Contract Fill/Finish SourceAntibodies

29 January 2012

Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS in Front-line Mature T-Cell LymphomasAntibodies

29 January 2012

Seattle Genetics Announces Data from ADCETRIS in Cutaneous T-Cell Lymphoma and Peripheral T-Cell LymphomaAntibodies

26 January 2012

ASCEND Study to Evaluate the Effectiveness of TYSABRI® (natalizumab) as a Treatment for Secondary-Progressive Multiple SclerosisAntibodies

25 January 2012

Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALINAntibodies

24 January 2012

Baxter to Initiate Second Phase III Trial Studying GAMMAGARD LIQUID (IGIV) for the Treatment of Alzheimer’s DiseaseAntibodies

23 January 2012

ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in “CANCER”, the Journal of the American Cancer SocietyAntibodies

21 January 2012

Remicade® (Infliximab) Receives Positive Opinion From CHMP In Europe for Treatment of Ulcerative Colitis in Pediatric PatientsAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

DLL3-Targeted Immunotherapy Candidates Pipeline Review

Adalimumab (Humira) Biosimilars Pipeline Review

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review

Nectin-4-Targeted Immunotherapy Pipeline Review

Report Package: Bispecific Antibodies

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

TROP-2-Targeted Immunotherapy Pipeline Review

CCR8-Targeted Antibody Immunotherapy Pipeline Review